Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer

Abstract Background Nuclear factor erythroid 2–related factor 2 (Nrf2) is involved in cell proliferation by promotion of metabolic activity. It is also the major regulator of antioxidants and has a pivotal role in tumor cell proliferation and resistance to chemotherapy. Accordingly, we investigated...

Full description

Bibliographic Details
Main Authors: Yoshiyuki Yamaguchi, Takao Kamai, Satoru Higashi, Satoshi Murakami, Kyoko Arai, Hiromichi Shirataki, Ken-Ichiro Yoshida
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12885-019-6347-0
id doaj-5e687974239c4eb7aab67d24ffdbadd9
record_format Article
spelling doaj-5e687974239c4eb7aab67d24ffdbadd92020-11-25T04:11:50ZengBMCBMC Cancer1471-24072019-11-011911910.1186/s12885-019-6347-0Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancerYoshiyuki Yamaguchi0Takao Kamai1Satoru Higashi2Satoshi Murakami3Kyoko Arai4Hiromichi Shirataki5Ken-Ichiro Yoshida6Department of Urology, Dokkyo Medical UniversityDepartment of Urology, Dokkyo Medical UniversityDepartment of Molecular and Cell Biology, Dokkyo Medical UniversityDepartment of Urology, Dokkyo Medical UniversityDepartment of Urology, Dokkyo Medical UniversityDepartment of Molecular and Cell Biology, Dokkyo Medical UniversityDepartment of Urology, Dokkyo Medical UniversityAbstract Background Nuclear factor erythroid 2–related factor 2 (Nrf2) is involved in cell proliferation by promotion of metabolic activity. It is also the major regulator of antioxidants and has a pivotal role in tumor cell proliferation and resistance to chemotherapy. Accordingly, we investigated the role of Nrf2 in renal cell carcinoma (RCC). Methods In 50 patients who had metastatic RCC and received cytoreductive nephrectomy, we performed Nrf2 gene mutation analysis using targeted next-generation sequencing, as well as investigating a specific single nucleotide polymorphism (SNP; rs6721961) in the Nrf2 promoter region and Nrf2 protein expression. Results Targeted next-generation sequencing revealed that five tumors had SNPs of Nrf2 associated with amino acid sequence variation, while 11 tumors had SNPs of Kelch-like ECH-associated protein 1 gene, 35 had SNPs of von Hippel-Lindau gene, and none had SNPs of fumarate hydratase gene. The three genotypes of rs6721961 showed the following frequencies: 60% for C/C, 34% for C/A, and 6% for A/A. Nrf2 mutation and the C/A or A/A genotypes were significantly associated with increased Nrf2 protein expression (p = 0.0184 and p = 0.0005, respectively). When the primary tumor showed Nrf2 gene mutation, the C/A or A/A genotype, or elevated Nrf2 protein expression, the response of metastases to vascular endothelial growth factor-targeting therapy was significantly worse (p = 0.0142, p = 0.0018, and p <  0.0001, respectively), and overall survival was significantly reduced (p = 0.0343, p = 0.0421, and p <  0.0001, respectively). Elevated Nrf2 protein expression was also associated with shorter survival according to multivariate Cox proportional analysis. Conclusion These findings suggest an associated between progression of RCC and Nrf2 signaling.http://link.springer.com/article/10.1186/s12885-019-6347-0Nuclear factor erythroid 2–related factor 2 (Nrf2)Kelch-like ECH-associated protein 1 (Keap1)Single nucleotide polymorphismRenal cell carcinoma
collection DOAJ
language English
format Article
sources DOAJ
author Yoshiyuki Yamaguchi
Takao Kamai
Satoru Higashi
Satoshi Murakami
Kyoko Arai
Hiromichi Shirataki
Ken-Ichiro Yoshida
spellingShingle Yoshiyuki Yamaguchi
Takao Kamai
Satoru Higashi
Satoshi Murakami
Kyoko Arai
Hiromichi Shirataki
Ken-Ichiro Yoshida
Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer
BMC Cancer
Nuclear factor erythroid 2–related factor 2 (Nrf2)
Kelch-like ECH-associated protein 1 (Keap1)
Single nucleotide polymorphism
Renal cell carcinoma
author_facet Yoshiyuki Yamaguchi
Takao Kamai
Satoru Higashi
Satoshi Murakami
Kyoko Arai
Hiromichi Shirataki
Ken-Ichiro Yoshida
author_sort Yoshiyuki Yamaguchi
title Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer
title_short Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer
title_full Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer
title_fullStr Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer
title_full_unstemmed Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer
title_sort nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the nrf2 promoter region in renal cell cancer
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2019-11-01
description Abstract Background Nuclear factor erythroid 2–related factor 2 (Nrf2) is involved in cell proliferation by promotion of metabolic activity. It is also the major regulator of antioxidants and has a pivotal role in tumor cell proliferation and resistance to chemotherapy. Accordingly, we investigated the role of Nrf2 in renal cell carcinoma (RCC). Methods In 50 patients who had metastatic RCC and received cytoreductive nephrectomy, we performed Nrf2 gene mutation analysis using targeted next-generation sequencing, as well as investigating a specific single nucleotide polymorphism (SNP; rs6721961) in the Nrf2 promoter region and Nrf2 protein expression. Results Targeted next-generation sequencing revealed that five tumors had SNPs of Nrf2 associated with amino acid sequence variation, while 11 tumors had SNPs of Kelch-like ECH-associated protein 1 gene, 35 had SNPs of von Hippel-Lindau gene, and none had SNPs of fumarate hydratase gene. The three genotypes of rs6721961 showed the following frequencies: 60% for C/C, 34% for C/A, and 6% for A/A. Nrf2 mutation and the C/A or A/A genotypes were significantly associated with increased Nrf2 protein expression (p = 0.0184 and p = 0.0005, respectively). When the primary tumor showed Nrf2 gene mutation, the C/A or A/A genotype, or elevated Nrf2 protein expression, the response of metastases to vascular endothelial growth factor-targeting therapy was significantly worse (p = 0.0142, p = 0.0018, and p <  0.0001, respectively), and overall survival was significantly reduced (p = 0.0343, p = 0.0421, and p <  0.0001, respectively). Elevated Nrf2 protein expression was also associated with shorter survival according to multivariate Cox proportional analysis. Conclusion These findings suggest an associated between progression of RCC and Nrf2 signaling.
topic Nuclear factor erythroid 2–related factor 2 (Nrf2)
Kelch-like ECH-associated protein 1 (Keap1)
Single nucleotide polymorphism
Renal cell carcinoma
url http://link.springer.com/article/10.1186/s12885-019-6347-0
work_keys_str_mv AT yoshiyukiyamaguchi nrf2genemutationandsinglenucleotidepolymorphismrs6721961ofthenrf2promoterregioninrenalcellcancer
AT takaokamai nrf2genemutationandsinglenucleotidepolymorphismrs6721961ofthenrf2promoterregioninrenalcellcancer
AT satoruhigashi nrf2genemutationandsinglenucleotidepolymorphismrs6721961ofthenrf2promoterregioninrenalcellcancer
AT satoshimurakami nrf2genemutationandsinglenucleotidepolymorphismrs6721961ofthenrf2promoterregioninrenalcellcancer
AT kyokoarai nrf2genemutationandsinglenucleotidepolymorphismrs6721961ofthenrf2promoterregioninrenalcellcancer
AT hiromichishirataki nrf2genemutationandsinglenucleotidepolymorphismrs6721961ofthenrf2promoterregioninrenalcellcancer
AT kenichiroyoshida nrf2genemutationandsinglenucleotidepolymorphismrs6721961ofthenrf2promoterregioninrenalcellcancer
_version_ 1724416717555236864